Connection

SUSAN HILSENBECK to Disease-Free Survival

This is a "connection" page, showing publications SUSAN HILSENBECK has written about Disease-Free Survival.
Connection Strength

0.321
  1. Making sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias? J Clin Oncol. 2012 Feb 01; 30(4):453-8.
    View in: PubMed
    Score: 0.081
  2. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998; 52(1-3):227-37.
    View in: PubMed
    Score: 0.031
  3. Retrospective review of genomic testing in breast cancer: Does it improve outcome? Breast Cancer Res Treat. 2017 May; 163(1):191-195.
    View in: PubMed
    Score: 0.029
  4. Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer. J Natl Cancer Inst. 1994 Dec 07; 86(23):1785-9.
    View in: PubMed
    Score: 0.025
  5. A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer. Oncologist. 2015 Jan; 20(1):13.
    View in: PubMed
    Score: 0.025
  6. Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PLoS One. 2012; 7(8):e30207.
    View in: PubMed
    Score: 0.021
  7. Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat. 2012 Feb; 132(1):61-73.
    View in: PubMed
    Score: 0.019
  8. Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer. Breast Cancer Res Treat. 2010 Oct; 123(3):651-60.
    View in: PubMed
    Score: 0.017
  9. Low SAFB levels are associated with worse outcome in breast cancer patients. Breast Cancer Res Treat. 2010 Jun; 121(2):503-9.
    View in: PubMed
    Score: 0.016
  10. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004 Apr 15; 10(8):2751-60.
    View in: PubMed
    Score: 0.012
  11. Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol. 2000 May; 18(9):1906-13.
    View in: PubMed
    Score: 0.009
  12. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol. 1999 Aug; 17(8):2334-40.
    View in: PubMed
    Score: 0.009
  13. Lack of prognostic value of cathepsin D levels for predicting short term outcomes of breast cancer patients. Cancer Lett. 1997 Jun 24; 116(2):177-83.
    View in: PubMed
    Score: 0.007
  14. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res. 1997 Jan; 3(1):103-9.
    View in: PubMed
    Score: 0.007
  15. Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. J Steroid Biochem Mol Biol. 1996 Nov; 59(3-4):251-60.
    View in: PubMed
    Score: 0.007
  16. The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res. 1996 Jul; 2(7):1199-206.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.